Pharmacogenomic knowledge gaps and educational resource needs among physicians in selected specialties

Katherine A Johansen Taber
Barry D Dickinson

Department of Science and Biotechnology, American Medical Association, Chicago, IL, USA

Background: The use of pharmacogenomic testing in the clinical setting has the potential to improve the safety and effectiveness of drug therapy, yet studies have revealed that physicians lack knowledge about the topic of pharmacogenomics, and are not prepared to implement it in the clinical setting. This study further explores the pharmacogenomic knowledge deficit and educational resource needs among physicians.

Materials and methods: Surveys of primary care physicians, cardiologists, and psychiatrists were conducted.

Results: Few physicians reported familiarity with the topic of pharmacogenomics, but more reported confidence in their knowledge about the influence of genetics on drug therapy. Only a small minority had undergone formal training in pharmacogenomics, and a majority reported being unsure what type of pharmacogenomic tests were appropriate to order for the clinical situation. Respondents indicated that an ideal pharmacogenomic educational resource should be electronic and include such components as how to interpret pharmacogenomic test results, recommendations for prescribing, population subgroups most likely to be affected, and contact information for laboratories offering pharmacogenomic testing.

Conclusion: Physicians continue to demonstrate pharmacogenomic knowledge gaps, and are unsure about how to use pharmacogenomic testing in clinical practice. Educational resources that are clinically oriented and easily accessible are preferred by physicians, and may best support appropriate clinical implementation of pharmacogenomics.

Keywords: pharmacogenomics, knowledge gap, drug response, educational resource

Introduction

The application of genomics to clinical care has grown tremendously over the last decade. Nearly every baby born in the US undergoes a continually expanding battery of genetic tests within days of birth,1 gene-expression patterns are routinely analyzed to predict prognosis and guide treatment of malignancies,2 and most recently, whole-genome sequencing has been successfully applied to solve diagnostic dilemmas not amenable to more traditional approaches.3 However, many physicians have reported inadequate knowledge about genetics and a lack of confidence in using genomic-based technologies in the clinic.4 5 This educational gap has been cited as a substantial barrier to the implementation of genomic technologies in clinical care.9–15

The clinical availability of pharmacogenomic tests, ie, tests that detect inherited genetic variations that influence individual response to drugs, has grown rapidly. This growth has been fueled in part by compelling statistics on adverse drug reactions (ADRs); ADRs occur in nearly 10% of patients taking prescription medications in the
ambulatory setting and cause an estimated 100,000 deaths each year in hospitalized patients in the US. Genetic differences account for a substantial amount of patient variability in drug response and disposition, and more than a quarter of primary care patients are taking a medication that commonly causes ADRs and is under the control of genetically variable factors. In an effort to inform prescribers about the potential for ADRs, the US Food and Drug Administration (FDA) has steadily updated the labeling of drugs that are subject to variable patient response in those carrying certain genetic variations. The labeling of more than 100 drugs now contains such pharmacogenomic information. Approximately 25% of outpatients are being treated with a medication that includes pharmacogenomic information in the labeling.

Despite the relatively common practice of prescribing drugs with pharmacogenomic properties, most physicians report the same unfamiliarity with pharmacogenomic testing as they do with genomic technologies in general. Few primary care physicians believe they are well informed about the role of pharmacogenomic testing in therapeutic decision making, and a majority report that they are uncomfortable ordering a pharmacogenomic test.

Several types of educational resources have been developed with the goals of familiarizing physicians and other health professionals with pharmacogenomics, increasing the appropriate clinical use of pharmacogenomic testing, targeting therapy to responsive patients, and decreasing the occurrence of certain preventable ADRs. These resources include stand-alone continuing medical education programs, print materials like brochures and fact sheets, and point-of-care resources, such as integrated clinical decision support. To inform the continued development of pharmacogenomic resources that will be most useful for physicians, we conducted a survey of physicians in three specialty disciplines (primary care, psychiatry, and cardiology). Our goal was to better understand prescribing behaviors and physician experience with pharmacogenomic testing, and to explore physicians’ preferred characteristics of an ideal pharmacogenomics resource.

Materials and methods
Survey development and sample recruitment
Survey questions were developed collaboratively and subjected to several rounds of revision by staff in the American Medical Association (AMA) Science and Biotechnology and Market Research groups. Question development was informed by reviews of clinical implementation of pharmacogenomics and previous surveys of physicians, and by existing AMA staff expertise. The survey consisted of approximately 30 questions exploring knowledge and attitudes about pharmacogenomics, and ten demographic questions. Question types were 1) Likert-type scale, using the categories “strongly disagree”, “disagree”, “neither agree nor disagree”, “agree”, and “strongly agree” to indicate confidence in knowledge of the influence of patient genetics on the response to drug therapy; 2) semantic differential scale type, in which respondents were asked preferences for educational resource format on scale of 1–5, with 1 being most preferred and 5 being least preferred; and 3) multiple-choice questions about pharmacogenomic training, pharmacogenomic test-ordering behavior, drugs subject to variable clinical response due to genetic variation, currently consulted pharmacogenomic resources, content to be included in resources, preferred source to develop educational resources, and demographics. Respondents were allowed to enter more than one answer on multiple-choice questions, unless only one answer was appropriate, such as in “yes/no” questions. Some multiple-choice questions included the choice “other”, with a “please specify” request allowing entry of free text. The complete survey is available in the Supplementary material section.

Survey questions were programmed into the Qualtrics (Provo, UT, USA) survey program to develop an online survey site. A survey invitation was sent in October 2011 through Epocrates (San Mateo, CA, USA) to US office-based physicians between the ages of 25 and 64 years who use the service; the invitation included a link to the online survey. The survey was terminated for respondents indicating that they specialized in an area other than primary care, psychiatry, or cardiology. Primary care physicians, psychiatrists, and cardiologists were targeted because collectively they care for patients with a wide array of conditions, a number of which may be treated with drugs that are known to elicit variable responses in patients with certain genetic variations, and because those specialties are not as routinely reliant on pharmacogenomic testing as are some specialties, such as oncology. The survey was fielded for approximately 2 weeks. A total of 305 respondents met the demographic and specialty criteria, but five did not complete the entire survey. The survey was terminated when 300 primary care physicians, psychiatrists, and cardiologists had completed it. The survey was anonymous; respondent names were not collected.
Data analysis
Survey data were analyzed using SPSS (IBM, Armonk, NY, USA). To determine significance, t-tests were used for means and z-tests for column proportions, both with a 95% confidence level. In some cases, categories of Likert-type and semantic differential scale responses were collapsed, eg, combining “extremely important” and “very important”, combining “strongly agree” and “somewhat agree”, and combining responses of 1 and 2 on a 1–5 preference scale. For cases in which response categories were combined, notation is included in the corresponding figure or table. Participant characteristics were summarized using descriptive statistics.

Results
Study-group characteristics
Characteristics of survey participants are summarized in Table 1. Of 300 physicians, approximately 60% were primary care physicians (including family physicians, general physicians, and internists); the remaining 40% of participants were split nearly equally between psychiatrists and cardiologists. Participants had a mean of 10.3 (±1.59) years in postresidency/fellowship practice, and spent a mean of 48.6 (±7.51) hours per week in direct patient contact. More than three-quarters of participants used smartphones and/or computers to access health care-related information. Approximately three-quarters of primary care physician and cardiologist respondents, and approximately half of psychiatrist respondents, used an electronic medical record (EMR) system. Comparison with AMA Physician Masterfile data showed that sex and geographic region of the survey sample were generally representative of the physician population. Survey participants tended to be younger than the general physician population, with participants aged 25–34 and 35–44 years overrepresented, and participants aged 45–54 years underrepresented among the respondents.

Prescribing attitudes
To understand further the relative importance physicians place on genetic information when making decisions about drug therapy, survey participants were asked to report how much importance they place on several factors, including genetic information, when choosing drug therapy and/or dosing regimens. Medical history and adverse effects were the factors most commonly cited by respondents as extremely or very important (94.3% and 92.7%, respectively), followed by age, labeled indication, and whether the drug is covered by insurance (66.0%, 62.3%, and 58.0%, respectively) (Figure 1). A patient’s genetic information was reported as

Table 1 Characteristics of survey population (n=300)

| Characteristics                      | Total respondents (n) |
|--------------------------------------|-----------------------|
| Sex                                  |                       |
| Male                                 | 68.7% (206)           |
| Female                               | 31.3% (94)            |
| Age, years                           |                       |
| 25–34                                | 24.3% (73)            |
| 35–44                                | 53.7% (161)           |
| 45–54                                | 3.7% (11)             |
| 55–64                                | 18.3% (55)            |
| Years in practice (postresidency/fellowship) | 10.3±1.59        |
| Hours of direct patient care per week| 48.6±7.51             |
| Medical specialty                    |                       |
| Family medicine*                     | 38.3% (115)           |
| General medicine*                    | 0.7% (2)              |
| Internal medicine*                   | 21.3% (64)            |
| Psychiatry                           | 20.0% (60)            |
| Cardiology                           | 19.7% (59)            |
| Region                               |                       |
| Northeast                            | 21.3% (64)            |
| Midwest                              | 19.3% (58)            |
| South                                | 36.7% (110)           |
| West                                 | 22.7% (68)            |
| Practice setting                     |                       |
| Physician office, solo               | 14.3% (43)            |
| Physician office, single-specialty group | 53.3% (160)          |
| Multispecialty group practice        | 32.3% (97)            |
| Uses an EMR                          |                       |
| Primary care physicians              | 77.3% (140/181)*      |
| Psychiatrists                         | 51.7% (31/60)         |
| Cardiologists                         | 72.9% (43/59)         |
| Devices used to access health care-related information |               |
| Desktop computer                     | 75.7% (227)           |
| Laptop computer                      | 76.3% (229)           |
| Tablet computer                      | 33.3% (100)           |
| Smartphone                            | 80.0% (240)           |

Notes: *Grouped together as primary care physicians; †significantly more primary care physicians than psychiatrists reported using an EMR (P<0.05).
Abbreviation: EMR, electronic medical record.

Figure 1 Factors cited as extremely or very important by physician respondents when choosing appropriate drug therapy or dosage.
Notes: Psychiatrists were significantly less likely than primary care physicians and cardiologists to report that labeled indication is extremely or very important when making prescribing decisions (38.3% versus 66.9% and 72.9%, respectively, P<0.05).
extremely or very important by only 27.0% of respondents (Figure 1); an approximately equal number of respondents (28.0%) reported genetic information as not very or not at all important (not shown).

Knowledge of pharmacogenomics
When asked to rank their familiarity with pharmacogenomics, 12.6% of respondents reported being extremely or very familiar with the topic (Figure 2). After reporting their familiarity with pharmacogenomics, participants encountered the following statement: “Pharmacogenomics is the influence of genetic differences on human variability in drug response.” They were then asked if they agreed that they were confident in their knowledge of the influence of genetics on drug therapy; 37.0% of respondents reported that they strongly or somewhat agreed with the statement (Figure 2). Only 11% reported that they had received formal training in pharmacogenomics (Figure 2); medical school (66.7%), residency training (57.6%), and continuing medical education (CME) programs (48.5%) were the most commonly cited settings in which the training had occurred (not shown).

To determine whether self-reported confidence in knowledge of the influence of genetics on drug therapy was an accurate indicator of actual knowledge, survey participants were asked to indicate, to the best of their knowledge, whether each of several commonly prescribed drugs (presented in a list format) “elicit substantially variable responses due to a patient’s genetic background.” Wide variation in responses was received, roughly correlating with specialty (Table 2). For example, 86.4% and 64.4% of cardiologists correctly indicated that clopidogrel and warfarin (both commonly prescribed to treat cardiology-related conditions), respectively, elicit variable responses due to genetic background.

Similarly, 43.3% and 21.7% of psychiatrists correctly indicated that carbamazepine and atomoxetine (both commonly prescribed to treat psychiatric-related conditions), respectively, elicit variable responses due to genetic background. Each specialty group showed knowledge deficits. For example, only 7% and 5% of primary care and cardiologist respondents, respectively, correctly indicated that metoprol (used primarily to treat hypertension) elicits variable responses based on genetic background. Significantly more psychiatrists than primary care physicians or cardiologists (41.7% versus 19.3% and 6.8%, respectively) reported that they did not know whether one or more of the drugs could elicit a substantially variable response due to a patient’s genetic background.

Pharmacogenomic test ordering
Nearly 20% of survey respondents indicated that they had ordered a pharmacogenomic test during the last year, with significantly more cardiologists than psychiatrists having ordered a test (32.2% versus 11.7%, P<0.05; not shown).

When those who indicated that they had not ordered a pharmacogenomic test in the past year were asked why they had not, the most common answers were not knowing what test to order (69.7%), lack of insurance coverage (52.7%), and uncertainty about the clinical value of the test (51.9%) (Figure 3). Other answers were not applicable for patients (17.8%), patient declined test (5.0%), and privacy concerns (5.0%) (not shown). Significantly more primary care physicians than cardiologists reported that they did not know what test to order (75.0% versus 52.5%, P<0.05).

Respondents also were asked whether they anticipated ordering a pharmacogenomic test in the next year, with 49.7% answering in the affirmative; no significant differences were noted among the specialties. Those who indicated that they did not plan to order a pharmacogenomic test in the next year were asked why they would not. The most common responses were similar to reasons cited for not having ordered a test in the past year: 76.8% indicated they would not know what test to order, 62.9% indicated that they would be uncertain of the test’s clinical value, and 48.3% indicated that insurance would not cover the test (Figure 3). Other responses were not applicable for patients (17.9%), patient likely to decline test (10.6%), and privacy concerns (6.6%) (not shown). Significantly more primary care physicians and psychiatrists than cardiologists reported that they would not know what test to order (84.6% and 83.9%, respectively, versus 44.8%; P<0.05).

For those who indicated that they had ordered a pharmacogenomic test in the past year, we asked, in the form...
Table 2 Proportion of respondents indicating that the drug listed could elicit a substantially variable response due to a patient’s genetic background

| Drug       | Biomarker(s) | Total % (n) | PCP % (n) | Psychiatrists % (n) | Cardiologists % (n) |
|------------|--------------|-------------|-----------|---------------------|---------------------|
| Warfarin†  | CYP2C9       | 47.7 (143)  | 51.9 (94) | 18.3 (11)           | 64.4 (38)           |
|            | VKORC1       |             |           |                     |                     |
| Clopidogrel (Plavix®)†  | CYP2C19     | 47.0 (141)  | 47.0 (85) | 8.3 (5)             | 86.4 (51)           |
| Atorvastatin (Lipitor®)† | LDL-R       | 24.7 (74)   | 28.2 (51) | 11.7 (7)            | 27.1 (16)           |
| Carbamazepine (Tegretol®)† | HLA-B*1502  | 21.0 (63)   | 18.2 (33) | 43.3 (26)           | 6.8 (4)             |
| Quinidine  |              | 14.3 (43)   | 16.0 (29) | 8.3 (5)             | 15.3 (9)            |
| Captopril (Capoten®) |            | 13.3 (40)   | 14.9 (27) | 6.7 (4)             | 15.3 (9)            |
| Fluconazole (Diflucan®) |          | 13.0 (39)   | 14.9 (27) | 10.0 (6)            | 10.2 (6)            |
| Hydrochlorothiazide |            | 10.7 (32)   | 13.8 (25) | 8.3 (5)             | 3.4 (2)             |
| Levothyroxine (Synthroid®) |        | 10.7 (32)   | 14.4 (26) | 6.7 (4)             | 3.4 (2)             |
| Atomoxetine (Strattera®)† | CYP2D6     | 7.7 (23)    | 5.0 (9)   | 21.7 (13)           | 1.7 (1)             |
| Metoprolol (Lopressor®)† | CYP2D6     | 6.3 (13)    | 7.2 (13)  | 5.0 (3)             | 5.1 (3)             |
| Don’t know |              | 21.3 (64)   | 19.3 (35) | 41.7 (25)           | 6.8 (4)             |
| Total      |              | (300)       | (181)     | (60)                | (59)                |

Notes: †Correct answer (drug elicits substantially variable response due to genetic variation); drugs included on this list are those that are among the most frequently prescribed by the specialties participating in the survey; those considered correct answers have clear pharmacogenomic information in the drug labeling, as well as substantial evidence of pharmacogenomic influence published in the literature; value significantly higher than corresponding value in “Psychiatrists” column (P<0.05); ‡value significantly higher than corresponding values in “PCP” and “Cardiologists” columns (P<0.05); §value significantly higher than corresponding values in “PCP” and “Psychiatrists” columns (P<0.05). Manufacturer details are as follows: Plavix® (Par Pharmaceutical, spring Valley, nY, USA); synthroid® (Sanofi, Bridgewater, New Jersey, USA); Lipitor® (Pfizer, Inc., New York, NY, USA); Tegretol® and Lopressor® (Novartis International AG, Basel, Switzerland); Capoten® (Per Pharmaceutical, Spring Valley, NY, USA); Synthroid® (Abbott Laboratories, North Chicago, IL, USA); Strattera® (Ell Lilly and Company, Indianapolis, IN, USA). Abbreviation: PCP, primary care physician.

of a free-text field, what type of test was ordered. Among those who answered the question, 43% named tests associated with clopidogrel and warfarin. Approximately 25% of respondents named a test that is not a pharmacogenomic test, eg, “BRCA”, “cystic fibrosis”, “hemochromatosis”, and “Huntington’s disease”.

Current pharmacogenomic resources
To gain an understanding of the pharmacogenomic educational resources currently used by physicians, survey participants were asked to indicate from a list of resource types which type they most often consult when they have questions about pharmacogenomics. Scientific literature (58.0%), the Internet (49.3%), professional society literature/recommendations (47.3%), and peer discussions (41.7%) were the most commonly cited (Table 3). Less commonly cited were laboratory directors/personnel (25.0%), drug labeling (20.7%), the FDA website (17.7%), and insurance companies/payers (11.3%) (Table 3). A small percentage of respondents (14.3%) indicated that they...
had not consulted any resources. Primary care physicians were significantly more likely than cardiologists to have consulted a laboratory director/personnel (29.8% versus 11.9%, \(P<0.05\)), and primary care physicians and psychiatrists were significantly more likely than cardiologists to have consulted the FDA website (18.8% and 26.7%, respectively, versus 5.1%; \(P<0.05\)). When asked whether currently available resources enable them to access the pharmacogenomic information you need or want to know, yes were represented by 43.0% (129) and no by 57.0% (171).

### Ideal pharmacogenomic resource

When asked to indicate from a list of content topics which should be included in an ideal pharmacogenomic resource, the most commonly cited answers were how to interpret pharmacogenomic test results (88.4%), recommendations for prescribing (88.1%), effect of genetic variation on mechanism of drug action (79.9%), and demographics of populations likely to carry variations (76.9%) (Table 4). Other content preferences among respondents included references such as scientific literature (69.0%), a list of laboratories offering testing (63.9%), and a description of pharmacogenomic information in drug labeling (62.2%) (Table 4). Other responses, submitted as free text, included the price of tests and whether they were covered by insurance. Significantly more psychiatrists than cardiologists indicated that information on how to interpret pharmacogenomic test results (96.7% versus 82.5%, \(P<0.05\)) and a description of pharmacogenomic information in drug labeling (75.0% versus 52.5%, \(P<0.05\)) should be included in an ideal resource.

Survey participants were asked to rate on a scale of 1–5, with 1 being most preferred and 5 being least preferred, what type of format they would prefer for an ideal pharmacogenomic resource. A web-based format was ranked as a 1 or 2 by 67.7% of respondents, mobile application for smartphone or tablet was ranked as 1 or 2 by 56.2% of respondents, and incorporated within an EMR system was ranked as a 1 or 2 by 34.0% of respondents (Table 4). Primary care physicians were significantly more interested in EMR incorporation than were psychiatrists (41.2% rating it as a 1 or 2 versus 16.6% rating it as a 1 or 2, \(P<0.05\)).

### Table 3 Resources currently consulted when questions arise about pharmacogenomics

| Resources | Total respondents (n) |
|-----------|-----------------------|
| Scientific literature | 58.0% (174) |
| Internet (Google searches, WebMD, etc) | 49.3% (148) |
| Professional society literature/guidelines/recommendations | 47.3% (142) |
| Peer discussion | 41.7% (125) |
| Laboratory directors/personnel | 25.0% (75)* |
| Drug labeling | 20.7% (62) |
| FDA website | 17.7% (53)* |
| Insurance company/payer | 11.3% (34) |
| Have not consulted resources | 14.3% (43) |

*Primary care physicians were significantly more likely than cardiologists to have consulted a laboratory director/personnel (29.8% versus 11.9%, \(P<0.05\)); primary care physicians and psychiatrists were significantly more likely than cardiologists to have consulted the US Food and Drug Administration (FDA) website (18.8% and 26.7%, respectively, versus 5.1%; \(P<0.05\)).

### Table 4 Preferred characteristics of an ideal pharmacogenomic educational resource

| Characteristics | Total respondents (n) |
|-----------------|-----------------------|
| Content | |
| How to interpret pharmacogenomic test results | 88.4% (260)* |
| Recommendations for prescribing | 88.1% (259) |
| Effect of genetic variation on mechanism of drug action | 79.9% (235) |
| Demographics of populations likely to carry variations | 76.9% (226) |
| References (such as scientific literature) | 69.0% (203) |
| List of laboratories offering testing | 63.9% (188) |
| Description of pharmacogenomic information in drug labeling | 62.2% (183)* |
| Format | |
| Web-based | 67.7% (199) |
| Mobile application (for smartphone or tablet) | 56.2% (165) |
| Incorporated within EMR | 34.0% (100)* |
| Pop-up reminders within prescribing system | 23.4% (69) |
| Print materials | 18.7% (55) |
| Source (organization or institution) | |
| Health care-related software company (eg, Epocrates) | 66.9% (200) |
| Professional/specialty society | 19.4% (58) |
| Government | 6.7% (20) |
| Health insurance company | 5.7% (17) |

*Values represent combined ratings of 1 or 2 on a scale of 1–5, with 1 representing most preferred and 5 representing least preferred; significantly more psychiatrists than cardiologists indicated that content on how to interpret pharmacogenomic test results (96.7% versus 82.5%, \(P<0.05\)) and a description of pharmacogenomic information in the drug labeling (75.0% versus 52.5%, \(P<0.05\)) should be included; primary care physicians were significantly more interested in EMR incorporation than were psychiatrists (41.2% rating it as a 1 or 2 versus 16.6% rating it as a 1 or 2, \(P<0.05\)).

**Abbreviation:** EMR, electronic medical record.
Survey participants also were asked to indicate which of the listed organization or institution types would be their preferred source to develop a pharmacogenomic resource. Respondents reported that they most preferred a health care-related software company (66.9%) (Table 4); Epocrates was included as an example of a health care-related software company. Professional/specialty societies (19.4%), government (6.7%), and health insurance companies (5.7%) were also named (Table 4). Answers written in as free text included “pharmacy experts” and a number of specific medical specialty societies.

Discussion
The pharmacogenic knowledge deficit among physicians suggests the need for educational resources that will support clinical implementation of pharmacogenomics when appropriate. To determine what type of resource may be most valuable to physicians, we sought to understand further their knowledge and attitudes about pharmacogenomics, use of pharmacogenomic testing, use of current educational resources, and preferred characteristics of an ideal educational resource among physicians in selected specialties. Results suggest that physicians continue to experience a pharmacogenomics knowledge deficit, and prefer educational resources that are clinically oriented.

Assessment of attitudes and knowledge gaps
Given the imperative for safe and effective drug therapy, the importance that physicians place on a patient’s medical history (diagnosis, reason for drug therapy) and the potential for adverse effects (possible drug interactions, past drug intolerance or adverse event) when making prescribing decisions is not surprising. Other studies examining factors that influence prescribing decisions have reported similar results.37,38 However, since nearly all physicians believe genetic variations influence drug response,22 it was somewhat unexpected that few respondents in our survey considered genetic information extremely or very important. Our study and others have shown deficiencies in physicians’ knowledge of the influence of genetics on drug therapy,22,23,39,40 so it is possible that physicians acknowledge the importance of genetic variation on drug response but that their gap in knowledge on the topic negatively impacts their attitude about its importance in prescribing decisions. Another possibility is that respondents considered medical history as being inclusive of genetic information. Similarly, adverse reactions often arise when a patient carries a genetic variation affecting drug metabolism or response, so respondents may have considered genetic information as contributing to the overall potential for adverse effects.

Our study shows that familiarity with the concept of pharmacogenomics remains low, with just 12.6% indicating that they were extremely or very familiar with it. Similarly, a study by Haga et al revealed that only 13% of respondents felt well informed about the role of pharmacogenomics in therapeutic decision making,23 and Stanek et al showed that only approximately 10% of respondents felt they were adequately informed about the applicability of genetic testing to drug therapy.22 Our study further reveals that there may be a misunderstanding about the meaning of the term “pharmacogenomics”; the number of respondents reporting that they were confident in their knowledge about the influence of genetics on drug response was several-fold higher than the number reporting familiarity with pharmacogenomics (Figure 2). Few physicians may be aware that pharmacogenomics is, at its most basic, the influence of genetic variation on drug response. This possibility is supported by reported difficulties experienced by physicians and other health professionals asked to describe the concept of pharmacogenomics; confusion about the purpose of pharmacogenomic testing and the process of test ordering and interpretation was apparent among participants in Fargher et al.41 In addition to the need for resources that can assist physicians in using pharmacogenomic technologies when clinically appropriate, our results point to the need for consistent terminology that makes it clear that in the clinical context, the term “pharmacogenomics” means the awareness that genetic variations could result in a patient’s suboptimal response to a drug.

Our direct assessment of pharmacogenomic knowledge by asking survey respondents to pick, from a list of commonly prescribed drugs, those that could elicit a substantially variable response based on a patient’s genetic background was consistent with the modest proportion reporting confidence in their knowledge of the influence of genetics on drug therapy. Answering correctly tended to correlate with specialty, ie, drugs commonly prescribed by a certain specialty were more likely to be identified by that specialty as potentially eliciting a variable response due to genetic background. Encouragingly, a large majority of cardiologists correctly identified clopidogrel as potentially eliciting a variable response (Table 2), perhaps due to a recently added boxed warning on its labeling noting that the drug is less effective in people who cannot metabolize it to its active form, and to heavy television marketing of the drug.
that included messaging about genetic variations that reduce its effectiveness. Important knowledge gaps were apparent, however. Few primary care physicians or cardiologists indicated that metoprolol has the potential for variable response, and only about half of primary care physicians indicated that clopidogrel and warfarin have the potential for variable response (Table 2). This is despite the fact that these three drugs are among the most commonly prescribed in the US.\textsuperscript{42} We are not aware of other studies that have directly assessed physicians’ pharmacogenomic knowledge gaps, but our results are consistent with studies that have found physicians’ self-reported knowledge to be low.\textsuperscript{22,23,39}

Physicians who have embraced the utility of pharmacogenomic testing tend to be those who acknowledge receiving formal training in it (medical school, residency, or continuing medical education).\textsuperscript{22} However, coursework covering pharmacogenomic concepts is limited in medical schools: only approximately a quarter of medical schools include more than 4 hours of pharmacogenomics coursework in their curricula, and three-quarters of medical schools consider their own pharmacogenomics curriculum to be poor or inadequate.\textsuperscript{43} Several recommendations have been made to improve pharmacogenomics and more generally genomic training in medical school and residency programs.\textsuperscript{34–36,42} Similarly, it is thought that continuing medical education programs that are more integrated into the clinical routine and that emphasize applicable practical skills improvement are more likely to bring about sustained changes than are passive, stand-alone courses.\textsuperscript{9,10,35} Suggested external forces that may drive the improvement of formal pharmacogenomic education are the inclusion of pharmacogenomic-focused questions on licensure examinations, the threat of malpractice litigation once pharmacogenomic information is included in drug labeling, and patients’ increasing interest in direct-to-consumer genetic testing services.\textsuperscript{47}

**Clinical uptake of pharmacogenomics**

Clinical integration of pharmacogenomic testing appears to be on the rise, based on the number of physicians who anticipate ordering a pharmacogenomic test in the next year. That number, nearly 50\%, was more than twice the number reporting that they had ordered a pharmacogenomic test in the last year, and is similar to previously reported increases between pharmacogenomic test-ordering behavior in the recent past compared to anticipated pharmacogenomic test ordering.\textsuperscript{22} However, when respondents were asked to name the pharmacogenomic tests they had ordered or anticipated ordering, a quarter named a genetic test not related to pharmacogenomics. This further underscores the notion that physicians may not understand the term “pharmacogenomics”, and calls into question whether the increase in the number of physicians who plan to order a “pharmacogenomic test” in the next year is a valid indicator of increasing clinical adoption. Accurate estimates of clinical adoption may be best accomplished by directly studying the number of pharmacogenomic tests ordered from several laboratories over time, rather than by relying on physicians’ recollection and anticipated behavior.

The lack of evidence supporting the clinical utility of pharmacogenomic testing is often cited as a barrier to its integration.\textsuperscript{10,34–36,48} In our survey, uncertainty about the clinical value of the test was cited as a reason for not having ordered or not anticipating ordering a pharmacogenomic test (Figure 3), but it was not the most commonly cited reason. Rather, more physicians reported being unsure about what pharmacogenomic test to order, suggesting that the knowledge gap is a larger barrier among physicians than a perceived lack of evidence. Since nearly all physicians believe that genetic variations influence drug response,\textsuperscript{22} it has been suggested that the knowledge gap may be more practical, such as not knowing what tests are available, where to order them, or how to interpret their results, rather than foundational.\textsuperscript{42,22} Selkirk et al demonstrated that physicians who have had experience caring for a patient who has undergone pharmacogenomic testing have a higher level of understanding of factors related to the genetic testing process,\textsuperscript{39} and Stanek et al concluded that experience with pharmacogenomic testing may improve the genetics knowledge gap among physicians and drive appropriate clinical uptake.\textsuperscript{22} Our results are supportive of such suggestions, and further indicate that point-of-care resources that address practical questions about test ordering and interpretation are needed.

**Educational resources for practicing physicians**

Appropriate integration of pharmacogenomics into the clinical setting depends in part on addressing the identified knowledge gap among physicians using educational resources that will best meet the needs of practicing physicians. Although physicians in our survey named a number of resources that they had consulted, more than half reported that they were not able to get the information they needed or wanted from them. These results are consistent with others reporting that physicians are not completely satisfied with commonly available genomic education resources.\textsuperscript{39} It is not clear whether
survey participants were sufficiently aware of currently available pharmacogenomic resources; answers may have been based on only those resources of which they were aware. Respondents indicated a desire for a “physician-friendly” resource that contains information most pertinent to therapeutic decision making for individual patients: guidance on how to interpret pharmacogenomic test results and recommendations for prescribing based on such results, the effect of genetic variation on drug action, and a listing of laboratories offering pharmacogenomic testing were among the most highly preferred components.

While several resources containing pharmacogenomic information exist, many do not include the type of information that our study participants reported they need or want in an ideal resource. For example, the FDA maintains a list of drugs with labeling that includes mention of pharmacogenomic biomarkers. While this is a useful inventory of drugs affected by genetic variation, few drug labels include specific dosage information for patients with certain genotypes or information about how to interpret pharmacogenomic test results. The Indiana University Division of Clinical Pharmacology maintains a table of drugs metabolized by cytochrome P450 enzymes, including references for associated studies. The information is valuable, but is not meant to be a clinical guide for physicians. A notable exception is the Pharmacogenomics Knowledge Base (PharmGKB). Over the last few years, the amount of clinical information available on its website has steadily increased, including dosing guidelines, the effect of selected genetic variations on drug action, and information about which laboratories perform the genetic test(s) specific to each drug. The PharmGKB database also includes straightforward overviews of the mechanism of drug action, links to drug labeling, references, and genotype-based prescribing guidelines developed by the Clinical Pharmacogenetics Implementation Consortium. Since this resource seems to include the type of information our study participants reported they want in an ideal resource, yet more than half of participants reported that they were not able to get the information they wanted from current resources, we believe that they may not be aware of PharmGKB or other resources like it that may indeed meet their needs. Efforts to increase awareness of currently available resources should be undertaken, and may partially address the pharmacogenomics knowledge gap.

Electronic resources, such as websites or mobile applications, are clearly preferred by physicians in our study. This is not surprising, since more than three-quarters of participants said they access health care-related information using smartphones and/or computers, a number that appears to be reflective of national trends. Clinical decision support, ie, educational information integrated into an EMR system and tailored to the clinical situation, has been promoted as a potentially valuable point-of-care resource for pharmacogenomics. For example, if a drug known to cause variable response depending on a patient’s genotype is prescribed, the EMR would alert the prescriber and provide links to more detailed information, including pharmacogenomic testing options; or, if a patient’s genotype is known, alerts are tailored based on which drugs would be subtherapeutic or potentially result in an adverse event for that patient. This type of clinical decision support has been instituted within the EMR systems of several medical centers, with early analyses suggesting that it successfully guides appropriate prescribing.

Physicians in our study trust a number of different sources to develop educational resources, with health care-related software companies at the top of the list. Since the survey was delivered through Epocrates, we believe some bias may exist in the choice of a health care-related software company. Another preferred source is a professional/specialty society. Collaboration on the development of pharmacogenomic resources between health care-related software companies and professional/specialty societies, or endorsement of an existing resource, such as PharmGKB or an EMR-integrated clinical decision-support system by a professional/specialty society, may foster trust in the source while increasing awareness and uptake of the resource among members of the professional/specialty society.

As medical home- and team-based care models proliferate, other health professionals may act as pharmacogenomic resources for physicians. For example, a collaboration between pharmacists and physicians has been tested, in which pharmacogenomic testing is initiated at the pharmacy and then the prescribing physician receives the results of the test and is given the opportunity to alter prescription details. During the study period, prescriptions were altered for approximately half of participating patients. Similarly, genetic counselors have been proposed as an integral part of the pharmacogenomic delivery team because of their expertise in risk communication and counseling methodology. Genetic counselors may be particularly important when pharmacogenomic testing is undertaken to guide treatment for conditions that are genetic in nature. It should be noted that both pharmacists and genetic counselors may have pharmacogenomics knowledge deficits, and that they too require educational resources.
Study limitations

Our study had limitations that should be noted. The survey sample was small, and although the sample appeared to be representative of the sex and geographic location of the physician population, generalizations about the larger physician population should be made cautiously. Younger physicians (aged 25–44 years) were overrepresented in our survey sample; since previous studies have shown that early adopters of genetic technologies tend to be those who have graduated from medical school most recently, our study sample may have included more early adopters than the general physician population. Further, since the survey was delivered electronically through Epocrates, our study sample may have been overrepresented by those who are comfortable with technology. Also, the survey participants knew some information about the focus of the study, since the invitation noted that the survey was about genetics in medical practice, and thus may have been more likely than the general physician population to be interested in and familiar with genetics and/or pharmacogenomics.

Conclusion

In this study, we explored the pharmac genomic knowledge gaps demonstrated by many physicians, and their preferences for educational resources that meet their clinical pharmacogenomic needs. We found that familiarity with pharmacogenomics continues to be low and that knowledge gaps persist, possibly driven by a misunderstanding of what “pharmacogenomics” means. Educational resources tailored to physicians’ needs are desired, with the preferred format being electronic. Resources that are seamlessly integrated into a physician’s daily work routine and are supported or vetted by professional societies seem most likely to contribute to appropriate clinical implementation of pharmacogenomics.

With the advent of next-generation sequencing technologies, the amount of genomic information poised to impact clinical care has vastly increased. Improved outcomes for patients who have undergone pharmacogenomic testing prior to being administered certain medications have been demonstrated, with more trials under way. However, mechanisms to prepare physicians for the appropriate use of pharmacogenomic information are urgently needed. The amount of clinical information about pharmacogenomics has become so great and continues to expand so rapidly that physicians cannot possibly learn and develop the necessary skills to apply it from traditional formal training. Information available at the point of care, targeted to the clinical situation at hand, is most likely to be meaningful and to promote improved outcomes for patients. Collaboration among a broad number of stakeholders, such as that being undertaken by the National Human Genome Research Institute’s Intersociety Coordinating Committee, is likely to be most successful in addressing educational resource deficits by reaching a large number of physicians in many specialty areas. As a federation organization representing all 50 US state medical societies and more than 100 medical specialty societies, the AMA is particularly suited to act as a convener to promote improved resource development.

Acknowledgments

The authors wish to thank members of the AMA Market Research staff for their assistance in developing and fielding the survey. We also thank Modena Wilson, MD, MPH (AMA) for her helpful comments on the manuscript. The work presented in this paper was supported by the AMA.

Disclosure

The authors report no conflicts of interest in this work.

References

1. National Newborn Screening and Genetics Resource Center. National newborn screening status report. 2013. Available from: http://genes-r-us.uthscsa.edu/sites/genes-r-us/files/nbsdisorders.pdf. Accessed March 5, 2014.
2. Awada A, Vandone AM, Aftimos P. Personalized management of patients with solid cancers: moving from patient characteristics to tumor biology. Curr Opin Oncol. 2012;24(3):297–304.
3. Johansen Taber KA, Dickinson BD, Wilson M. The promise and challenges of next-generation genome sequencing for clinical care. JAMA Intern Med. 2014;174(2):275–280.
4. Kließman R, Chung W, Marder K, et al. Attitudes and practices among internists concerning genetic testing. J Genet Couns. 2013;22(1):90–100.
5. Harvey EK, Fogel CE, Peyrot M, Christensen KD, Terry SF, McInerney JD. Providers’ knowledge of genetics: a survey of 5915 individuals and families with genetic conditions. Genet Med. 2007;9(5):259–267.
6. Baars MJ, Henneman L, Ten Kate LP. Deficiency of knowledge of genetics and genetic tests among general practitioners, gynecologists, and pediatricians: a global problem. Genet Med. 2005;7(9):605–610.
7. Korf BR, Feldman G, Wiesner GL. Report of Banbury Summit meeting on training of physicians in medical genetics, October 20–22, 2004. Genet Med. 2005;7(6):433–438.
8. Suther S, Goodson P. Barriers to the provision of genetic services by primary care physicians: a systematic review of the literature. Genet Med. 2003;5(2):70–76.
9. McInerney JD, Edelman E, Nissen T, Reed K, Scott JA. Preparing health professionals for individualized medicine. Per Med. 2012;9(5):529–537.
10. Feeero WG, Green ED. Genomics education for health care professionals in the 21st century. JAMA. 2011;306(9):989–990.
11. Safiri K. The dawning era of personalized medicine exposes a gap in medical education. PLoS Med. 2009;6(8):e1000138.
12. Scheunet MT, Sieverding P, Shekelle PG. Delivery of genomic medicine for common chronic adult diseases: a systematic review. JAMA. 2008;299(11):1320–1334.
13. Guttmacher AE, Porteous ME, Mcinerney JD. Educating healthcare professionals about genetics and genomics. Nat Rev Genet. 2007;8(2):151–157.

14. Secretary's Advisory Committee on Genetics, Health, and Society. Genetics Education and Training. Bethesda (MD): Department of Health and Human Services; 2011. Available from: http://osp.od.nih.gov/sites/default/files/SACGHS_education_report_2011.pdf. Accessed March 5, 2014.

15. Hamilton AB, Oishi S, Yano EM, Gamage CE, Marshall NJ, Scheuner MT. Factors influencing organizational adoption and implementation of clinical genetic services. Genet Med. 2014;16(3):238–245.

16. Taché SV, Sönnichsen A, Ashcroft DM. Prevalence of adverse drug events in ambulatory care: a systematic review. Ann Pharmacother. 2011;45(7–8):977–989.

17. Lazarou J, Pomeranz B, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279(15):1200–1205.

18. Evans WE, McLeod HL. Pharmacogenomics: drug disposition, drug targets and side effects. N Engl J Med. 2003;348(6):538–549.

19. Grice GR, Seaton TL, Woodland AM, McLeod HL. Defining the growing genetic pharmacology market. Nat Rev Genet. 2006;7(11):61–65.

20. US Food and Drug Administration. Table of pharmacogenomic biomarkers in drug labeling. Available from: http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm083378.htm. Accessed March 5, 2014.

21. Fruehw, Amur S, Mummaneni P, et al. Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use. Pharmacotherapy. 2008;28(8):992–998.

22. Stanek EJ, Sanders CL, Johansen Taber KA, et al. Adoption of pharmacogenomics into routine medical record. Pharmacogenomics. 2011;12(2):149–153.

23. Haga SB, Burke W, Ginsburg GS, Mills R, Agans R. Primary care physicians' knowledge of and experience with pharmacogenetic testing. Clin Genet. 2012;82(4):388–394.

24. McDonagh EM, Whirl-Carrillo M, Garten Y, Altman RB, Klein TE. From pharmacogenomic knowledge acquisition to clinical applications: the PharmGKB as a clinical pharmacogenomic biomarker resource. Biomark Med. 2011;5(267):795–806.

25. Kuo GM, Ma JD, Lee KC, et al. Institutional Profile: University of California San Diego Pharmacogenomics Education Program (PharmGenEd™): bridging the gap between science and practice. Pharmacogenomics. 2011;12(2):149–153.

26. Hicks JK, Crews KR, Hoffman JM, et al. A clinician-driven automated system for integration of pharmacogenetic interpretations into an electronic medical record. Clin Pharmacol Ther. 2012;92(5):563–566.

27. Pulley JM, Denny JC, Peterson JF, et al. Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT project. Clin Pharmacol Ther. 2012;92(1):87–95.

28. Johnson JA, Burkle BM, Langae TY, Clare-Salzler MJ, Klein TE, Altman RB. Implementing personalized medicine: development of a cost-effective customized pharmacogenetics genotyping array. Clin Pharmacol Ther. 2012;92(4):437–439.

29. O'Donnell PH, Bush A, Spitz J, et al. The 1200 patients project: creating a new medical model system for clinical implementation of pharmacogenomics. Clin Pharmacol Ther. 2012;92(4):446–449.

30. American Medical Association, Critical Path Institute, Arizona Center for Research and Education on Therapeutics. Pharmacogenomics: Increasing the Safety and Effectiveness of Drug Therapy. Chicago: AMA; 2011. Available from: http://www.ama-assn.org/resources/doc/genetics/pgx-brochure-2011.pdf. Accessed March 5, 2013.

31. American Medical Association, Critical Path Institute, Arizona Center for Research and Education on Therapeutics. Personalized Health Care Report 2008: Warfarin and Genetic Testing. Chicago: AMA; 2008. Available from: http://www.ama-assn.org/resources/doc/genetics/warfarin-brochure.pdf. Accessed March 5, 2014.

32. GeneFacts.org. Pharmacogenetics fact sheets. Available from: http://genefacts.org/index.php?option=com_content&view=article&id=392&Itemid=457. Accessed March 5, 2014.

33. Ray T. FDA/AMA launch free online course aiming to improve basic PGx literacy. 2007. Available from: http://www.genomeweb.com/dxpgx/fdaama-launch-free-online-course-aiming-improve-basic-pgx-literacy. Accessed March 5, 2014.

34. Johnson J. Pharmacogenetics in clinical practice: how far have we come and where are we going? Pharmacogenomics. 2013;14(7):835–843.

35. Manolio TA, Chisholin RL, Ozenberger B, et al. Implementing genomic medicine in the clinic: the future is here. Genet Med. 2013;15(4):258–267.

36. Crews KR, Hicks JK, Pui CH, Relling MV, Evans WE. Pharmacogenomics and individualized medicine: translating science into practice. Clin Pharmacol Ther. 2012;92(4):467–475.

37. Schumock GT, Walton SM, Park HY, et al. Factors that influence prescribing decisions. Ann Pharmacother. 2004;38(4):557–562.

38. Nutescu EA, Park HY, Walton SM, et al. Factors that influence prescribing within a therapeutic drug class. J Eval Clin Pract. 2005;11(4):357–365.

39. Selkirk CG, Weissman SM, Anderson A, Hulick PJ. Physicians’ preparedness for integration of genomic and pharmacogenetic testing into practice within a major healthcare system. Genet Test Mol Biomarkers. 2013;17(3):219–225.

40. Bonter K, Desjardins C, Currier N, Pun J, Ashbury FD. Personalised medicine in Canada: a survey of adoption and practice in oncology, cardiology and family medicine. BMJ Open. 2011;1(1):e000110.

41. Farrger EA, Eddy C, Newman W, et al. Patients’ and healthcare professionals’ views on pharmacogenetic testing and its future delivery in the NHS. Pharmacogenomics. 2007;8(11):1511–1519.

42. Bartholow M. Top 200 drugs of 2012. Pharm Times. 2013;79(7). Available from: http://www.pharmacymtimes.com/publications/issue/2013/July2013/Top200Drugs-of-2012. Accessed March 5, 14.

43. Green JS, O’Brien TJ, Chiappinelli VA, Harrellson AF. Pharmacogenomics instruction in US and Canadian medical schools: implications for personalized medicine. Pharmacogenomics. 2010;11(9):1331–1340.

44. Gurwitz D, Lunshof JE, Dedoussis G, et al. Pharmacogenomics education: International Society of Pharmacogenomics recommendations for medical, pharmaceutical, and health schools deans of education. Pharmacogenomics J. 2005;5(4):221–225.

45. Korf B. Genetics and genomics education: the next generation. Genet Med. 2011;13(3):201–202.

46. Howard Hughes Medical Institute, American Association of Medical Colleges. Scientific Foundations for Future Physicians: Report of the AAMC-HHMI Committee. Washington: AAMC; 2009. Available from: https://www.aamc.org/download/271072/data/scientificfoundationsforfuturephysicians.pdf. Accessed June 16, 2014.

47. Nickola TJ, Green JS, Harrellson AF, O’Brien TJ. The current and future state of pharmacogenomics medical education in the USA. Pharmacogenomics. 2012;13(12):1419–1425.

48. Khoury MJ, Coates RJ, Evans JP. Evidence-based classification of recommendations on use of genomic tests in clinical practice: dealing with insufficient evidence. Genet Med. 2010;12(11):680–683.

49. Indiana University Division of Clinical Pharmacology. P450 drug interaction table. Available from: http://medicine.iupui.edu/clinpharm/ddis/main-table. Accessed March 5, 2014.

50. Pharmacogenomics Knowledge Base [website on the Internet]. Available from: http://www.pharmgkb.org. Accessed March 5, 2014.

51. Ozdalga E, Ozdalga A, Neera A. The smartphone in medicine: a review of current and potential use among physicians and students. J Med Internet Res. 2012;14(5):e128.

52. Putzer GJ, Park Y. Are physicians likely to adopt emerging mobile technologies? Attitudes and innovation factors affecting smartphone use in the Southeastern United States. Perspect Health Inf Manag. 2012;9:1b.

53. Dressler LG. Integrating personalized genomic medicine into routine clinical care: addressing the social and policy issues of pharmacogenomic testing. NC Med J. 2013;74(6):509–513.
54. Peterson JF, Bowton E, Field JR, et al. Electronic health record design and implementation for pharmacogenomics: a local perspective. *Genet Med*. 2013;15(10):833–841.
55. Overby CL, Tarczy-Hornoch P, Hoath JI, Kalet IJ, Veenstra DL. Feasibility of incorporating genomic knowledge into electronic medical records for pharmacogenomic clinical decision support. *BMC Bioinformatics*. 2010;11 Suppl 9:S10.
56. Toner B. Cleveland clinic rolls out EHR-based program to alert docs about PGx tests for azathioprine, abacavir. 2013. Available from: http://cdnwww.genomeweb.com/clinical-genomics/cleveland-clinic-rolls-out-ehr-based-program-alert-docs-about-pgx-tests-azathiop. Accessed March 5, 2014.
57. Bell GC, Crews KR, Wilkinson MR, et al. Development and use of active clinical decision support for preemptive pharmacogenomics. *J Am Med Inform Assoc*. 2014;21(e1):e93–e99.
58. Schildcrout JS, Denny JC, Bowton E, et al. Optimizing drug outcomes through pharmacogenetics: a case for preemptive genotyping. *Clin Pharmacol Ther*. 2012;92(2):235–242.
59. O’Connor SK, Ferreri SP, Michaels NM, et al. Exploratory planning and implementation of a pilot pharmacogenetic program in a community pharmacy. *Pharmacogenomics*. 2012;13(8):955–962.
60. Teagarden RJ, Stanek EJ. On pharmacogenomics in pharmacy benefit management. *Pharmacotherapy*. 2012;32(2):103–111.
61. Ferreri SP, Greco AJ, Michaels NM, et al. Implementation of a pharmacogenomics service in a community pharmacy. *J Am Pharm Assoc (2003)*. 2014;54(2):172–180.
62. Mills R, Haga SB. Clinical delivery of pharmacogenetic testing services: a proposed partnership between genetic counselors and pharmacists. *Pharmacogenomics*. 2013;14(8):957–968.
63. Callard A, Newman W, Payne K. Delivering a pharmacogenetic service: is there a role for genetic counselors? *J Genet Couns*. 2012;21(4):527–535.
64. McCullough KB, Formea CM, Berg KD, et al. Assessment of the pharmacogenomics educational needs of pharmacists. *Am J Pharm Educ*. 2011;75(3):51.
65. Kuo GM, Lee KC, Ma JD. Implementation and outcomes of a live continuing education program on pharmacogenomics. *Pharmacogenomics*. 2013;14(8):885–895.
66. Epstein RS, Moyer TP, Aubert RE, et al. Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness Study). *J Am Coll Cardiol*. 2010;55(25):2804–2812.
67. Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. *N Engl J Med*. 2008;358(6):568–579.
68. Kimmel SE, French B, Anderson JL, et al. Rationale and design of the Clarification of Optimal Anticoagulation through Genetics trial. *Am Heart J*. 2013;166(3):435–441.
69. van Schie RM, Wadelius MI, Kamali F, et al. Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design. *Pharmacogenomics*. 2009;10(10):1687–1695.
70. Manolio TA, Murray MF. The growing role of professional societies in educating clinicians in genomics. *Genet Med*. Epub February 6, 2014.
Supplementary material
Survey of primary care physicians, cardiologists, and psychiatrists: pharmacogenomics knowledge, use of testing, and need for a pharmacogenomic resource

1. DEMOGRAPHICS
1. In what state do you currently practice medicine?
   (Fill-in text box)

2. Please select your gender.
   ○ Male
   ○ Female

3. Which of the following ranges contains your age?
   ○ 18–24
   ○ 25–34
   ○ 35–44
   ○ 45–54
   ○ 55–64
   ○ 65 or over

4. How many years have you been in practice since you completed your residency or fellowship?
   (Fill-in text box)

5. How many hours of direct patient care do you provide during a typical week?
   (Fill-in text box)

6. Please indicate which of the following best describes your medical specialty:
   ○ Allergy and immunology
   ○ Anesthesiology
   ○ Cardiology
   ○ Colon and rectal surgery
   ○ Dermatology
   ○ Emergency medicine
   ○ Endocrinology
   ○ Family medicine
   ○ Gastroenterology
   ○ Geriatrics
   ○ General medicine
   ○ Internal medicine
   ○ Nephrology
   ○ Neurology
   ○ Neurological surgery
   ○ Obstetrics and gynecology
   ○ Ophthalmology
   ○ Orthopaedic surgery
   ○ Otolaryngology
   ○ Pathology
   ○ Pediatrics
   ○ Physical medicine and rehabilitation
If answer to question 6 was not cardiology, family medicine, general medicine, internal medicine, or psychiatry, the survey was terminated at this point.

7. Which of the following best describes your primary practice setting?
   ○ Physician’s office, solo practice
   ○ Physician’s office, single specialty group practice
   ○ Multi-specialty group practice or clinic
   ○ Hospital, teaching
   ○ Hospital, non-teaching
   ○ Skilled nursing facility
   ○ Hospice
   ○ Urgent care facility
   ○ Home health agency
   ○ Other (please specify)

8. Do you use an electronic medical record (EMR) in your office?
   ○ Yes
   ○ No

9. Which, if any, of the following devices do you use to access healthcare-related information? Please select all that apply.
   ○ Smartphone
   ○ Tablet computer (eg, iPad)
   ○ Laptop/notebook computer
   ○ Desktop computer
   ○ Other (please specify)

II. CURRENT KNOWLEDGE/USAGE OF PHARMACOGENOMICS INFORMATION

How important are each of the following issues when choosing appropriate drug therapy/dosing regimens for your patients?
17. How familiar are you with pharmacogenomics?
   ○ Extremely familiar
   ○ Very familiar
   ○ Somewhat familiar
   ○ Not very familiar
   ○ Not at all familiar

Pharmacogenomics is the influence of genetic differences on the human variability in drug response. Please keep this definition in mind as you answer the following questions.

18. To what extent do you agree or disagree that you are confident in your knowledge about the influence of genetics on drug therapy?
   ○ Strongly agree
   ○ Somewhat agree
   ○ Neither agree nor disagree
   ○ Somewhat disagree
   ○ Strongly disagree

19. Have you had any type of formal training in pharmacogenomics?
   ○ Yes
   ○ No

If answer to question 19 was “Yes”:
19a. In which of the following types of settings have you received formal training in pharmacogenomics? Please select all that apply.
   ○ Medical school
   ○ Residency training
   ○ Continuing medical education programs (CME)
   ○ Other (please specify)

20. Have you ordered a pharmacogenomic test within the last year (2011)?
   ○ Yes
   ○ No

If answer to question 20 was “Yes”:
20a. What type of pharmacogenomic test(s) have you ordered in the last year (2011)? Please be specific in your response.
   (Fill-in text box)

If answer to question 20 was “No”:
20b. Which of the following issues explain why you haven’t ordered a pharmacogenomic test for a patient in the last year (2011)? Please select all that apply.
   ○ Don’t know what test to order
   ○ Insurance doesn’t cover test
   ○ Uncertain about clinical value of test
   ○ Not applicable for my patients
   ○ Patient declined test
   ○ Privacy concerns
   ○ Other (please specify)
21. Do you anticipate ordering a pharmacogenomic test in the next year (2012)?
   ○ Yes
   ○ No

If answer to question 21 was “Yes”:
21a. What type of pharmacogenomic test(s) do you anticipate ordering in the next year (2012)? Please be specific in your response.
   (Fill-in text box)

If answer to question 21 was “No”:
21b. Which of the following issues explain why you don’t anticipate ordering a pharmacogenomic test in the next year (2012)? Please select all that apply.
   ○ Won’t know what test to order
   ○ Insurance won’t cover test
   ○ Uncertain about clinical value of test
   ○ Not applicable for my patients
   ○ Patient likely to decline test
   ○ Privacy concerns
   ○ Other (please specify)

22. Which, if any, of the following sources of information do you consult when you have questions about pharmacogenomics? Please select all that apply.
   ○ Scientific literature
   ○ Peer discussions
   ○ Medical association literature/guidelines/recommendations
   ○ Internet (eg, Google searches, WebMD, etc)
   ○ Drug labeling
   ○ Laboratory director/personnel
   ○ FDA website
   ○ Insurance company/payer
   ○ Other (please specify)
   ○ None of the above, have not consulted any sources

23. Do you feel that there are resources currently available that enable you to access the pharmacogenomics information you need or want to know?
   ○ Yes
   ○ No

III. PHARMACOGENOMICS KNOWLEDGE ASSESSMENT
24. To the best of your knowledge, which sections of the drug product labeling could contain pharmacogenomic information? Please select all that apply.
   ○ Black-box warning
   ○ Clinical pharmacology
   ○ Clinical studies
   ○ Indications and uses
   ○ Dosage and administration
   ○ Warnings or precautions
   ○ Adverse reactions
25. How helpful do you find the pharmacogenomics information typically included in drug labeling?
- Extremely helpful
- Very helpful
- Somewhat helpful
- Not very helpful
- Not at all helpful

26. To the best of your knowledge, which of the following drugs elicit substantially variable population responses due to a patients' genetic background? Please select all that apply.
- Atomoxetine (Straterra®)
- Atorvastatin (Lipitor®)
- Captopril (Capoten®)
- Carbamazepine (Tegretol®)
- Clopidogrel (Plavix®)
- Fluconazole (Diflucan®)
- Hydrochlorothiazide
- Levo-thyroxine (Synthroid®)
- Metoprolol (Lopressor®)
- Quinidine
- Warfarin
- Don’t know

27. To the best of your knowledge, what is the most commonly recognized mechanism for pharmacogenomic differences in drug response? Is it mutations affecting … ?
- Drug metabolizing enzymes
- Cellular receptors or drug targets
- Membrane drug transporters
- Human leukocyte antigens
- Don’t know

28. Before today, were you aware of the abbreviation “CYP”? If yes, please explain.
- Yes
- No

29. To the best of your knowledge, approximately what percentage of the top 200 prescribed drugs is metabolized by an enzyme subject to pharmacogenomic variation?
- <10%
- 10%–25%
- 26%–50%
- 51%–75%
- >75%
- Don’t know
IV. CONCEPT OF IDEAL PHARMACOGENOMICS RESOURCE

30. Imagine an ideal resource that could be consulted when you have questions about pharmacogenomics or medications that may have pharmacogenomic properties. What type of content should be included in such a resource? Please select all that apply.
   ○ How to interpret pharmacogenomics test results
   ○ Description of pharmacogenomics information in drug labeling
   ○ Laboratories offering pharmacogenomic testing
   ○ Effect of genetic variation on mechanism of drug action
   ○ Recommendations (if any) for prescribing
   ○ Demographics of populations likely to carry genetic variations
   ○ References (scientific literature)
   ○ Other (please specify)

In which of the following types of formats would you prefer to use an ideal pharmacogenomics resource? Please rank each format by selecting a ‘1’ for your most preferred format, ‘2’ for your second most preferred format, and so on. A rank of ‘5’ represents your least preferred format. Use each number only once.

| Format                                                   | 1 | 2 | 3 | 4 | 5 |
|----------------------------------------------------------|---|---|---|---|---|
| 31. Web-based                                            |   |   |   |   |   |
| 32. Mobile application (for smartphone/tablet)           |   |   |   |   |   |
| 33. Print materials                                      |   |   |   |   |   |
| 34. Incorporated within an EMR system                    |   |   |   |   |   |
| 35. Pop-up reminders/information at time of prescription order |   |   |   |   |   |

36. Which of the following would be your preferred source for an ideal pharmacogenomic resource?
   ○ Professional/specialty society (please specify)
   ○ Health plans
   ○ Health care-related software company (eg, Epocrates)
   ○ Government
   ○ Other (please specify)